


ShanX Medtech B.V. secures a total of EUR 24 million to accelerate development of ultra-rapid antimicrobial susceptibility diagnostics

EINDHOVEN, The Netherlands, 07 January 2026 — ShanX Medtech B.V. (SXM), an innovative startup transforming how microbial infections are managed with its novel In-Vitro Diagnostic (IVD) platform, announces the closing of an oversubscribed EUR 15 million (~USD 17,5 million) seed funding round. The round combines multiple funding instruments including equity, grants and the Innovatiekrediet. The equity investment is led by the Borski Fund, NextGen Ventures, CbusineZ - an independent investment fund closely associated with healthcare insurer CZ - , Brabantse Ontwikkelings Maatschappij (BOM), Invest-NL, and a prominent strategic angel fund. This financing is further complemented by the recently awarded EUR 8,85 million (~USD 10,4 million) European Commission Contract (HADEA/2025/CPN/0006), developed by the Health Emergency Preparedness and Response Authority (DG HERA) in collaboration with the European Health and Digital Executive Agency (HADEA), bringing the total financing to EUR 24 million.

The innovation addresses one of the most urgent challenges in global healthcare today: the escalating threat of antimicrobial resistance (AMR). The obtained funding accelerates the final development, clinical validation, regulatory approval, and commercial launch of the SXM diagnostic platform, which is already seeing heavy interest from healthcare and commercial partners.

ShanX Medtech is transforming infection care with ultra-rapid, direct-from-sample antimicrobial susceptibility testing (AST). Using novel chemistry to monitor microbial metabolism, SXM delivers comprehensive results within an hour with minimal user involvement, representing a breakthrough improvement over current methods,



which require multiple trained technicians and take days to yield actionable results. By enabling faster, evidence-based treatment decisions in both laboratory and point-of-care settings, the platform has the potential to improve patient outcomes, reduce healthcare costs, curb the spread of AMR, and strengthen pandemic preparedness.

“We founded ShanX Medtech because of a single patient story, one that revealed how much is at stake when diagnostic results arrive too late,” said Dr. Sophia E.

Shanko, Founder and CEO of ShanX Medtech. “Our vision is to equip every clinician with the ability to act decisively, guided by diagnostic evidence in real-time. This funding brings us significantly closer to delivering ultra-rapid AST directly to both laboratory and point-of-care environments; faster, simpler, and more accessible than ever before.”

“Borski Fund is pleased to announce our investment in Eindhoven-based ShanX Medtech,” said Simone Brummelhuis, Partner at Borski Fund. “Following an extensive market analysis of innovations addressing antimicrobial resistance, ShanX’s technology clearly emerged as best-in-class. While the company’s initial go-to-market strategy focuses on a well-defined women’s health application in urinary tract infections, the underlying platform offers substantial potential across a wide range of clinical indications. We are proud to support Sophia and her exceptional team in realizing their ambitious vision. **The oversubscribed financing round, together with multiple multi-million-euro commercial contracts, underscores both the strength of the technology and the founder’s proven commercial execution.**”

“Antimicrobial resistance represents one of the most critical unmet needs in global healthcare, with few effective solutions available today,” said Paul Vernooij, Investment Manager at Brabant Development Agency (BOM). “**ShanX Medtech introduces a highly innovative technology that contributes preventively to global health.** As an early-stage investor, BOM is proud to take this next step alongside such a pioneering company.”

About ShanX Medtech

Founded in 2019, ShanX Medtech is a Dutch company based at the High Tech Campus in Eindhoven, The Netherlands. The company develops innovative In-Vitro Diagnostic (IVD) solutions that deliver ultra-rapid and accessible antimicrobial susceptibility testing, supporting global efforts to combat AMR and improve public health.

With 350+ MedTech companies and responsible for 90% of Dutch MedTech patents, the ecosystem in Eindhoven combines world-class research, advanced manufacturing, and entrepreneurial drive to accelerate healthcare solutions from idea to market.

For more information, please visit shanxmedtech.com or contact: info@shanxmedtech.nl